Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

282
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
282
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

413
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
413
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

339
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
339
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

228
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
228
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

591
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
591
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

365
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
365

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful Emergent Surgical Repair of Post-Myocardial Infarction Ventricular Septal Rupture With Cardiogenic Shock.

JACC. Case reports·2026
Same author

The Thickness That Deceives: The Role of Imaging, Biopsy, and Genetics in the Evaluation of Ventricular Hypertrophy.

Arquivos brasileiros de cardiologia·2026
Same author

The Trojan Horse Around the Heart: Pneumopericardium Revealing Gastropericardial Fistula.

JACC. Case reports·2026
Same author

Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Transthyretin or Light Chain Amyloidosis: A Real-World Analysis.

Arquivos brasileiros de cardiologia·2026
Same author

Underestimation of Stent Efficacy: Untreated Artery Events Distort Coronary Intervention Outcomes.

Clinical cardiology·2025
Same author

Effectiveness of a smartwatch-based feedback system in improving cardiopulmonary resuscitation quality: a simulation study.

Resuscitation plus·2025

Related Experiment Video

Updated: Dec 23, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K

Hypertrophic cardiomyopathy.

Murillo de Oliveira Antunes1,2, Thiago Luis Scudeler1

  • 1Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

International Journal of Cardiology. Heart & Vasculature
|April 21, 2020
PubMed
Summary
This summary is machine-generated.

Hypertrophic cardiomyopathy (HCM) is a common inherited heart condition with varied outcomes. This review covers clinical issues and treatment options for managing HCM symptoms and progression.

Keywords:
CMR, cardiac magnetic resonanceHCM, hypertrophic cardiomyopathyHF, heart failureISH, interventricular septal hypertrophyLVH, left ventricular hypertrophyLVOT, left ventricular outflow tractSAM, systolic anterior motionSCD, sudden cardiac death

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.7K

Related Experiment Videos

Last Updated: Dec 23, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.1K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.7K

Area of Science:

  • Cardiology
  • Genetics
  • Internal Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease.
  • HCM presents with diverse clinical manifestations, from asymptomatic cases to severe heart failure or sudden cardiac death.
  • Left ventricular hypertrophy and altered ventricular shape often lead to dynamic left ventricular outflow obstruction.

Purpose of the Study:

  • To review the key clinical issues associated with hypertrophic cardiomyopathy.
  • To summarize current pharmacological and therapeutic interventions for HCM.
  • To provide an overview of treatment strategies aimed at symptom alleviation and disease management.

Main Methods:

  • Literature review of clinical issues in hypertrophic cardiomyopathy.
  • Summary of current pharmacotherapies for HCM.
  • Overview of septal reduction therapies for HCM.

Main Results:

  • HCM is characterized by significant variability in presentation and progression.
  • Dynamic left ventricular outflow obstruction is common in HCM patients.
  • Pharmacological therapies and septal reduction therapies are primary treatment modalities.

Conclusions:

  • Effective management of HCM requires addressing its variable nature and potential complications.
  • Treatment goals focus on alleviating symptoms and improving the natural history of the disease.
  • A comprehensive understanding of clinical issues and treatment options is crucial for HCM patient care.